October 20, 2017 — Digital health company Analytics 4 Life announced it has completed a $25 million Series B financing. This financing event was supported by an international syndicate of accredited investors, including physicians, healthcare professionals and medical device experts. The company's novel cardiac imaging technology is under clinical investigation to help physicians assess the presence of coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents or cardiac stress.
Current diagnostic methods for CAD are costly, risky and time-consuming. Analytics 4 Life seeks to address these challenges with its novel method of cardiac imaging. The company's technology represents a new approach to cardiac imaging based on advanced disciplines of mathematics and physics combined with the power of cloud computing and artificial intelligence. The first application of this technology is CorVista, a non-invasive, physician-directed diagnostic test that aims to identify the presence of CAD without radiation or cardiac stress.
CorVista is designed to scan signals naturally emitted by the body with a synchronous array of seven sensors on Analytics 4 Life's proprietary collection device. After the signals are acquired, the signal package is instantaneously transmitted to the cloud where it is analyzed by a machine-learned algorithm to generate a unique image and a heart model indicating areas of potential heart disease associated with the presence of CAD. The results of the test are displayed on a secure physician web portal that, in combination with a patient's medical history, risk factors and symptoms, are used by the interpreting physician to recommend further treatment.
A two-stage clinical trial at 13 sites in the United States is currently underway to support CorVista's development and regulatory filings. The ongoing study, with more than 2,000 patients enrolled so far, will measure the performance of a machine-learned algorithm for CAD detection to gold-standard cardiac catheterization results.
Preliminary results will be presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) conference, Oct. 29-Nov. 2 in Denver. Assuming a positive U.S. Food and Drug Administration (FDA) review, the company anticipates having CorVista available in the U.S. next year.
For more information: www.analytics4life.com